CytomX Therapeutics, Inc. Shareholders' Equity
CytomX Therapeutics, Inc. (CTMX) had Shareholders' Equity of $302.07 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $302.07M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $319.94M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $99.01M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $107.39M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $302.07M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $319.94M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $99.01M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $107.39M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $119.91M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $25.05M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | -$456.00K 10-Q · filed 2026-08-06 | |
| 2024-09-30 | -$23.45M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$31.23M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | -$31.68M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | -$47.45M 10-K · filed 2026-03-16 | |
| 2023-09-30 | -$51.24M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$85.03M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | -$86.64M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | -$85.75M 10-K · filed 2025-03-06 | |
| 2022-09-30 | -$80.54M 10-Q · filed 2023-11-07 | $28.47M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$54.54M 10-Q · filed 2023-11-07 | $48.71M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$29.74M 10-Q · filed 2023-11-07 | $68.19M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$459.00K 10-K · filed 2024-03-11 | $89.38M 10-K · filed 2022-03-01 |
| 2021-09-30 | $30.43M 10-K/A · filed 2023-03-27 | $111.67M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $58.11M 10-K/A · filed 2023-03-27 | $130.95M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $80.67M 10-K/A · filed 2023-03-27 | $146.02M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$7.77M 10-K/A · filed 2023-03-27 | $49.80M 10-K · filed 2021-02-24 |
| 2020-09-30 | $48.06M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $58.83M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $69.77M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $25.47M 10-K/A · filed 2023-03-27 | $51.11M 10-K · filed 2020-02-27 |
| 2019-09-30 | $82.11M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $101.50M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $122.57M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $135.83M 10-K/A · filed 2023-03-27 | $130.88M 10-K · filed 2019-02-27 |
| 2018-09-30 | $157.66M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $41.13M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $49.65M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $69.90M 10-K · filed 2021-02-24 | |
| 2017-09-30 | $45.48M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $52.24M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $73.79M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $78.48M 10-K · filed 2020-02-27 | |
| 2016-09-30 | $89.42M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $101.19M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $112.71M 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $126.07M 10-K · filed 2019-02-27 | |
| 2015-09-30 | -$106.05M 10-Q · filed 2015-11-23 | |
| 2014-12-31 | -$78.54M 10-K · filed 2018-03-07 | |
| 2013-12-31 | -$44.28M 10-K · filed 2017-03-02 | |
| 2012-12-31 | -$26.05M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |